174 related articles for article (PubMed ID: 37574538)
1. Challenges in the care of patients with RET-altered thyroid cancer: a multicountry mixed-methods study.
Murray S; Subbiah V; Sherman SI; Péloquin S; Sireci A; Grohé C; Bubach P; Lazure P
Thyroid Res; 2023 Aug; 16(1):22. PubMed ID: 37574538
[TBL] [Abstract][Full Text] [Related]
2. Challenges in diagnosis and biomarker testing for RET-altered lung and thyroid cancer care: an international mixed-method study.
Lazure P; Sireci A; Subbiah V; Murray S; Grohé C; Sherman SI; Kelly E; Bubach P; Péloquin S
BMC Med Educ; 2023 Jun; 23(1):410. PubMed ID: 37277734
[TBL] [Abstract][Full Text] [Related]
3. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
[No Abstract] [Full Text] [Related]
4. Real-world clinical profile, treatment patterns and patient-reported outcomes for thyroid cancer in Japan.
Fukuda N; Tanizawa Y; Nakamura K; Okada Y; Segall G; Kiiskinen U; Fasnacht N; Sanderson I; Rider A; Lewis K
Future Oncol; 2023 May; 19(16):1125-1137. PubMed ID: 37278236
[TBL] [Abstract][Full Text] [Related]
5. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
Dabelić N; Jukić T; Fröbe A
Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
[TBL] [Abstract][Full Text] [Related]
6. Biomarker testing in patients diagnosed with advanced/metastatic medullary thyroid cancer in the USA.
Bhandari NR; Hess LM; Parikh RC; Sireci AN; Krein PM; Kaye JA
Per Med; 2023 Mar; 20(2):131-142. PubMed ID: 36749615
[TBL] [Abstract][Full Text] [Related]
7. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
[TBL] [Abstract][Full Text] [Related]
8. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
[TBL] [Abstract][Full Text] [Related]
9. Germline RET mutation carriers in Japanese patients with apparently sporadic medullary thyroid carcinoma: A single institution experience.
Kihara M; Miyauchi A; Yoshioka K; Oda H; Nakayama A; Sasai H; Yabuta T; Masuoka H; Higashiyama T; Fukushima M; Ito Y; Kobayashi K; Miya A
Auris Nasus Larynx; 2016 Oct; 43(5):551-5. PubMed ID: 26837867
[TBL] [Abstract][Full Text] [Related]
10. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
11. RET kinase inhibitors for
Vodopivec DM; Hu MI
Ther Adv Med Oncol; 2022; 14():17588359221101691. PubMed ID: 35756966
[TBL] [Abstract][Full Text] [Related]
12. Mutational analysis of the RET proto-oncogene in 71 Japanese patients with medullary thyroid carcinoma.
Shirahama S; Ogura K; Takami H; Ito K; Tohsen T; Miyauchi A; Nakamura Y
J Hum Genet; 1998; 43(2):101-6. PubMed ID: 9621513
[TBL] [Abstract][Full Text] [Related]
13. Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?
Romei C; Tacito A; Molinaro E; Agate L; Bottici V; Viola D; Matrone A; Biagini A; Casella F; Ciampi R; Materazzi G; Miccoli P; Torregrossa L; Ugolini C; Basolo F; Vitti P; Elisei R
Clin Endocrinol (Oxf); 2015 Jun; 82(6):892-9. PubMed ID: 25440022
[TBL] [Abstract][Full Text] [Related]
14. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
[TBL] [Abstract][Full Text] [Related]
15. Germline sequence variant S836S in the RET proto-oncogene is associated with low level predisposition to sporadic medullary thyroid carcinoma in the Spanish population.
Ruiz A; Antiñolo G; Fernández RM; Eng C; Marcos I; Borrego S
Clin Endocrinol (Oxf); 2001 Sep; 55(3):399-402. PubMed ID: 11589684
[TBL] [Abstract][Full Text] [Related]
16. [RET Gene Alterations in Thyroid Cancer-Towards Treatment with Selective RET Inhibitors].
Mitsutake N; Nakamura K; Suzuki S
Gan To Kagaku Ryoho; 2023 May; 50(5):611-614. PubMed ID: 37218322
[TBL] [Abstract][Full Text] [Related]
17. Chinese siblings with hereditary medullary thyroid carcinoma caused by RET mutation: implications for RET oncogene detection.
Huang Q; Hu A; Zhang M
BMC Endocr Disord; 2020 May; 20(1):64. PubMed ID: 32408902
[TBL] [Abstract][Full Text] [Related]
18. Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma.
D'Aloiso L; Carlomagno F; Bisceglia M; Anaganti S; Ferretti E; Verrienti A; Arturi F; Scarpelli D; Russo D; Santoro M; Filetti S
J Clin Endocrinol Metab; 2006 Mar; 91(3):754-9. PubMed ID: 16384843
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathology of hereditary and sporadic medullary thyroid carcinomas.
Chernock RD; Hagemann IS
Am J Clin Pathol; 2015 Jun; 143(6):768-77. PubMed ID: 25972318
[TBL] [Abstract][Full Text] [Related]
20. Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives.
Ceolin L; Duval MADS; Benini AF; Ferreira CV; Maia AL
Endocr Relat Cancer; 2019 Aug; 26(9):R499-R518. PubMed ID: 31252403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
